Ossur hf

Ossur hf

Health CareMedical Equipment and Services
  • Price (USD)4.90
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-18.40%
  • Beta--
Data delayed at least 15 minutes, as of Mar 13 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ossur hf is an Iceland-based company that operates within the field of medical equipment and supplies sector. The Company is active in the development and distribution of products in the fields of non-invasive prosthetics, medical braces and supports. The Company is divided into three market segments: Bracing and Supports, which offers products for therapeutic and preventive purposes; Prosthetics, which offers products for amputees, which include sockets, sleeves, prosthetic knees and feet, as well as supporting components, and Compression Therapy, which offers treatment for venous ulcers and edema. The Company's main markets are North America, Europe and Asia. It has subsidiaries in Iceland, the United States, Canada, Mexico, France, the Netherlands, the United Kingdom, Sweden, Norway, Spain, South Africa, China and Australia.

  • Revenue in DKK (TTM)4.94bn
  • Net income in DKK292.01m
  • Incorporated1971
  • Employees3.87k
  • Location
    Ossur hfGrjothals 5REYKJAVIK 110IcelandISL
  • Phone+354 5151300
  • Fax+354 5151366
  • Websitehttps://www.ossur.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
OSSR:CPH since
RCM Enterprise LLCDeal completed26 Aug 202226 Aug 2022Deal completed6.23%--
Data delayed at least 15 minutes, as of Mar 28 2023 15:59 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.